What is the strategic rationale behind GSK's £400m investment in a new Cambridge R&D centre, according to the article?

The article states that GSK’s investment is driven by the need to locate its UK R&D activities where world-class scientific infrastructure and clustering effects exist — specifically, the Cambridge biomedical campus, which hosts the University of Cambridge, Addenbrooke’s Hospital, multiple science institutes, and a vibrant biotech start-up ecosystem. This clustering is seen as essential for 'acceleration' of research and development, and the move also involves closing the historic Stevenage facility and relocating scientists to Cambridge. The article notes that Cambridge is a 'genuine world-class rival to Boston and Basel', and even suggests proximity to AstraZeneca’s facilities could be advantageous for future collaboration or merger possibilities.

What are the three key pillars of GSK’s current turnaround strategy as outlined in the article?

The article identifies three core elements: first, accelerating drug development — aiming to put at least 20 potential medicines into late-stage trials this year (up from 10), supported by the £8bn acquisition of Nuvalent and internal prioritisation under CEO Miels; second, delivering £1.9bn in annual cost savings by 2029 through procurement efficiencies, AI, leaner sales and manufacturing, and a strategic shift toward specialist drugs; third, mitigating the financial impact of the 2028–30 patent expiry of dolutegravir — which accounts for ~20% of group sales — by forecasting 'stable to improving' operating profit margins during that period, thanks to those cost savings, while reaffirming the £40bn+ revenue target for 2031 remains 'on track' with 'accelerating growth' thereafter.

GSK Announces £400m Cambridge R&D Centre Investment

Jul 29, 2026

GSK plans a £400m Cambridge R&D centre, closing its Stevenage facility. This strategic shift supports cost-cutting targets and drug pipeline acceleration despite near-term patent expiries.

theguardian

2026-07-29

GSK Announces £400m Cambridge R&D Centre Investment

GSK Announces £400m Cambridge R&D Centre Investment

FAQ